$3.63
-0.14[-3.71%]
At close: Apr 19
$3.63
0[0.00%]
After Hours: 4:20PM EDT
Sutro Biopharma
(NASDAQ:STRO)Sutro Biopharma Stock (NASDAQ:STRO), Analyst Ratings, Price Targets, Predictions
Sutro Biopharma Inc has a consensus price target of $14.75, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Oppenheimer, and Truist Securities on April 3, 2024. With an average price target of $13 between Piper Sandler, Oppenheimer, and Truist Securities, there's an implied 258.13% upside for Sutro Biopharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Oppenheimer
Truist Securities
JMP Securities
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Sutro Biopharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/03/2024 | STRO | Buy Now | Sutro Biopharma | $3.63 | 203.03% | Piper Sandler | Edward Tenthoff | $12 → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | STRO | Buy Now | Sutro Biopharma | $3.63 | 175.48% | Oppenheimer | Jay Olson | $10 → $10 | Maintains | Outperform | Get Alert |
| 04/03/2024 | STRO | Buy Now | Sutro Biopharma | $3.63 | 395.87% | Truist Securities | Asthika Goonewardene | $25 → $18 | Maintains | Buy | Get Alert |
| 04/03/2024 | STRO | Buy Now | Sutro Biopharma | $3.63 | 368.32% | JMP Securities | Reni Benjamin | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/28/2024 | STRO | Buy Now | Sutro Biopharma | $3.63 | 175.48% | Oppenheimer | Jay Olson | → $10 | Maintains | Outperform | Get Alert |
| 03/27/2024 | STRO | Buy Now | Sutro Biopharma | $3.63 | 175.48% | Oppenheimer | Jay Olson | $10 → $10 | Maintains | Outperform | Get Alert |
| 03/26/2024 | STRO | Buy Now | Sutro Biopharma | $3.63 | 120.39% | Wedbush | David Nierengarten | $12 → $8 | Maintains | Outperform | Get Alert |
| 03/26/2024 | STRO | Buy Now | Sutro Biopharma | $3.63 | 368.32% | JMP Securities | Reni Benjamin | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/26/2024 | STRO | Buy Now | Sutro Biopharma | $3.63 | 230.58% | HC Wainwright & Co. | Andrew Fein | → $16 | Maintains | Buy | Get Alert |
| 11/15/2023 | STRO | Buy Now | Sutro Biopharma | $3.63 | 230.58% | Piper Sandler | Edward Tenthoff | $18 → $12 | Maintains | Overweight | Get Alert |
| 11/14/2023 | STRO | Buy Now | Sutro Biopharma | $3.63 | 340.77% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | STRO | Buy Now | Sutro Biopharma | $3.63 | 230.58% | Deutsche Bank | James Shin | → $12 | Initiates | → Buy | Get Alert |
| 10/23/2023 | STRO | Buy Now | Sutro Biopharma | $3.63 | 230.58% | Wedbush | David Nierengarten | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 10/06/2023 | STRO | Buy Now | Sutro Biopharma | $3.63 | 175.48% | Oppenheimer | Jay Olson | → $10 | Initiates | → Outperform | Get Alert |
| 09/06/2023 | STRO | Buy Now | Sutro Biopharma | $3.63 | 588.71% | Truist Securities | Asthika Goonewardene | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | STRO | Buy Now | Sutro Biopharma | $3.63 | 368.32% | JMP Securities | Reni Benjamin | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/11/2023 | STRO | Buy Now | Sutro Biopharma | $3.63 | 340.77% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | STRO | Buy Now | Sutro Biopharma | $3.63 | 230.58% | Wedbush | David Nierengarten | $20 → $12 | Maintains | Outperform | Get Alert |
| 06/27/2023 | STRO | Buy Now | Sutro Biopharma | $3.63 | 368.32% | JMP Securities | Reni Benjamin | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
FAQ
What is the target price for Sutro Biopharma (STRO)?
The latest price target for Sutro Biopharma (NASDAQ: STRO) was reported by Piper Sandler on April 3, 2024. The analyst firm set a price target for $11.00 expecting STRO to rise to within 12 months (a possible 203.03% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sutro Biopharma (STRO)?
The latest analyst rating for Sutro Biopharma (NASDAQ: STRO) was provided by Piper Sandler, and Sutro Biopharma reiterated their overweight rating.
When was the last upgrade for Sutro Biopharma (STRO)?
There is no last upgrade for Sutro Biopharma.
When was the last downgrade for Sutro Biopharma (STRO)?
There is no last downgrade for Sutro Biopharma.
When is the next analyst rating going to be posted or updated for Sutro Biopharma (STRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sutro Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sutro Biopharma was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.
Is the Analyst Rating Sutro Biopharma (STRO) correct?
While ratings are subjective and will change, the latest Sutro Biopharma (STRO) rating was a reiterated with a price target of $12.00 to $11.00. The current price Sutro Biopharma (STRO) is trading at is $3.63, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.